-
1
-
-
84868366831
-
Health canada/biotecanada summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), ottawa: May 14, 2012
-
Kay J, Feagan BG, Guirguis MS, et al. Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa: May 14, 2012. Biologicals 2012;40:517-27.
-
(2012)
Biologicals
, vol.40
, pp. 517-527
-
-
Kay, J.1
Feagan, B.G.2
Guirguis, M.S.3
-
2
-
-
0141922918
-
Shifting paradigms: Biopharmaceuticals versus low molecular weight drugs
-
DOI 10.1016/S0378-5173(03)00376-4
-
Crommelin DJ, Storm G, Verrijk R, et al. Shifting paradigms: Biopharmaceuticals versus low molecular weight drugs. Int J Pharm 2003;266:3-16. (Pubitemid 37249303)
-
(2003)
International Journal of Pharmaceutics
, vol.266
, Issue.1-2
, pp. 3-16
-
-
Crommelin, D.J.A.1
Storm, G.2
Verrijk, R.3
De Leede, L.4
Jiskoot, W.5
Hennink, W.E.6
-
3
-
-
84856392773
-
Biosimilars: Current perspectives and future implications
-
Misra M. Biosimilars: Current perspectives and future implications. Indian J Pharmacol 2012;44:12-4.
-
(2012)
Indian J Pharmacol
, vol.44
, pp. 12-14
-
-
Misra, M.1
-
5
-
-
84867849193
-
Subsequent entry biologics/biosimilars: A viewpoint from canada
-
Russell AS, Ahluwalla V, Barnabe C, et al. Subsequent entry biologics/biosimilars: A viewpoint from Canada. Clin Rheumatol 2012;31:1289-92.
-
(2012)
Clin Rheumatol
, vol.31
, pp. 1289-1292
-
-
Russell, A.S.1
Ahluwalla, V.2
Barnabe, C.3
-
6
-
-
82155188444
-
Biosimilars: A regulatory perspective from america
-
Kay J. Biosimilars: A regulatory perspective from America. Arthritis Res Ther 2011;13:112.
-
(2011)
Arthritis Res Ther
, vol.13
, pp. 112
-
-
Kay, J.1
-
11
-
-
80053575082
-
The first subsequent entry biologic authorized for market in canada: The story of omnitrope, a recombinant human growth hormone
-
Klein AV. The first subsequent entry biologic authorized for market in Canada: The story of Omnitrope, a recombinant human growth hormone. Biologicals 2011;39:278-81.
-
(2011)
Biologicals
, vol.39
, pp. 278-281
-
-
Klein, A.V.1
-
12
-
-
0031972657
-
Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties
-
DOI 10.1046/j.1365-2141.1998.00521.x
-
Storring PL, Tiplady RJ, Gaines, et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998;100:79-89. (Pubitemid 28051844)
-
(1998)
British Journal of Haematology
, vol.100
, Issue.1
, pp. 79-89
-
-
Storring, P.L.1
Tiplady, R.J.2
Gaines Das, R.E.3
Stenning, B.E.4
Lamikanra, A.5
Rafferty, B.6
Lee, J.7
-
13
-
-
0035895071
-
Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin
-
Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001;98:3626-34.
-
(2001)
Blood
, vol.98
, pp. 3626-3634
-
-
Skibeli, V.1
Nissen-Lie, G.2
Torjesen, P.3
-
14
-
-
21444442363
-
Biosimilar epoetins: An analysis based on recently implemented European Medicines Evaluation Agency guidelines on comparability of biopharmaceutical proteins
-
DOI 10.1592/phco.2005.25.7.954
-
Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: An analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 2005;25:954-62. (Pubitemid 40917928)
-
(2005)
Pharmacotherapy
, vol.25
, Issue.7
, pp. 954-962
-
-
Combe, C.1
Tredree, R.L.2
Schellekens, H.3
-
15
-
-
58149388237
-
Effects of adalimumab maintenance therapy on health-related quality of life of patients with crohn's disease: Patient-reported outcomes of the charm trial
-
Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008;103:3132-41.
-
(2008)
Am J Gastroenterol
, vol.103
, pp. 3132-3141
-
-
Loftus, E.V.1
Feagan, B.G.2
Colombel, J.F.3
-
16
-
-
55449098725
-
Effects of adalimumab therapy on incidence of hospitalization and surgery in crohn's disease: Results from the charm study
-
Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: Results from the CHARM study. Gastroenterology 2008;135:1493-9.
-
(2008)
Gastroenterology
, vol.135
, pp. 1493-1499
-
-
Feagan, B.G.1
Panaccione, R.2
Sandborn, W.J.3
-
17
-
-
70349418632
-
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab
-
Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250-60.
-
(2009)
Gastroenterology
, vol.137
, pp. 1250-1260
-
-
Sandborn, W.J.1
Rutgeerts, P.2
Feagan, B.G.3
-
18
-
-
77950988234
-
Infliximab azathioprine or combination therapy for crohn's disease
-
Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
-
(2010)
N Engl J Med
, vol.362
, pp. 1383-1395
-
-
Colombel, J.F.1
Sandborn, W.J.2
Reinisch, W.3
-
19
-
-
84868514758
-
Inflammatory bowel disease: A canadian burden of illness review
-
Rocchi A, Benchimol EI, Bernstein CN, et al. Inflammatory bowel disease: A Canadian burden of illness review. Can J Gastroenterol 2012;26:811-7.
-
(2012)
Can J Gastroenterol
, vol.26
, pp. 811-817
-
-
Rocchi, A.1
Benchimol, E.I.2
Bernstein, C.N.3
-
20
-
-
84885593430
-
-
Green Shield Canada. Accessed March 14
-
Green Shield Canada. https://www.cutrust.com/employee/downloads/Benefits/ drugforms/ Drug%20Special%20Authorization%20Request%20Form%20for%20TNF%20Antagonists%20and %20Similar%20Biologics%20(2012-02).pdf(Accessed March 14, 2013).
-
(2013)
-
-
-
21
-
-
84873736952
-
A randomized, double-blind, phase 3 study demonstrates clinical equivalence of ct-p13 to infliximab when co-Administered with methotrexate in patients with active rheumatoid arthritis
-
Yoo D, Miranda P, Piotrowski M. A randomized, double-blind, phase 3 study demonstrates clinical equivalence of CT-P13 to infliximab when co-Administered with methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2012;71:359.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 359
-
-
Yoo, D.1
Miranda, P.2
Piotrowski, M.3
-
22
-
-
84867753437
-
A randomized, double-blind, phase 1 study demonstrates equivalence in pharmacokinetics, safety, and efficacy of ct-p13 and infliximab in patients with ankylosing spondylitis
-
Park W, Hrycaj P, Kovalenko V. A randomized, double-blind, phase 1 study demonstrates equivalence in pharmacokinetics, safety, and efficacy of CT-P13 and infliximab in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:111.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 111
-
-
Park, W.1
Hrycaj, P.2
Kovalenko, V.3
-
24
-
-
3042579454
-
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease
-
DOI 10.1016/S1542-3565(04)00238-1, PII S1542356504002381
-
Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53. (Pubitemid 38834038)
-
(2004)
Clinical Gastroenterology and Hepatology
, vol.2
, Issue.7
, pp. 542-553
-
-
Hanauer, S.B.1
Wagner, C.L.2
Bala, M.3
Mayer, L.4
Travers, S.5
Diamond, R.H.6
Olson, A.7
Bao, W.8
Rutgeerts, P.9
-
25
-
-
0037434552
-
Influence of immunogenicity on the long-Term efficacy of infliximab in crohn's disease
-
Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-Term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
-
(2003)
N Engl J Med
, vol.348
, pp. 601-668
-
-
Baert, F.1
Noman, M.2
Vermeire, S.3
-
26
-
-
70350130547
-
Influence of trough serum levels and immunogenicity on long-Term outcome of adalimumab therapy in crohn's disease
-
Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-Term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40.
-
(2009)
Gastroenterology
, vol.137
, pp. 1628-1640
-
-
Karmiris, K.1
Paintaud, G.2
Noman, M.3
-
27
-
-
34548130215
-
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
-
DOI 10.1136/gut.2006.099978
-
Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007;56:1226-31. (Pubitemid 47300423)
-
(2007)
Gut
, vol.56
, Issue.9
, pp. 1226-1231
-
-
Vermeire, S.1
Noman, M.2
Van Assche, G.3
Baert, F.4
D'Haens, G.5
Rutgeerts, P.6
-
28
-
-
33749432435
-
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for crohn's disease
-
DOI 10.1016/j.cgh.2006.06.025, PII S154235650600677X
-
Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-54. (Pubitemid 44512213)
-
(2006)
Clinical Gastroenterology and Hepatology
, vol.4
, Issue.10
, pp. 1248-1254
-
-
Maser, E.A.1
Villela, R.2
Silverberg, M.S.3
Greenberg, G.R.4
-
29
-
-
73449088039
-
Trough serum infliximab: A predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
-
Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: A predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut;59:49-54.
-
Gut
, vol.59
, pp. 49-54
-
-
Seow, C.H.1
Newman, A.2
Irwin, S.P.3
-
30
-
-
80455139421
-
Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: The uc success trial
-
Abst
-
Panaccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: The UC Success Trial. Gastroenterology 2011;140:A-202. (Abst)
-
(2011)
Gastroenterology
, vol.140
-
-
Panaccione, R.1
Ghosh, S.2
Middleton, S.3
-
31
-
-
47549097069
-
Epoetin-Associated pure red cell aplasia: Past, present, and future considerations
-
McKoy JM, Stonecash RE, Cournoyer D, et al. Epoetin-Associated pure red cell aplasia: Past, present, and future considerations. Transfusion 2008;48:1754-62.
-
(2008)
Transfusion
, vol.48
, pp. 1754-1962
-
-
McKoy, J.M.1
Stonecash, R.E.2
Cournoyer, D.3
-
32
-
-
0034754477
-
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
-
Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94. (Pubitemid 33022088)
-
(2001)
Gastroenterology
, vol.121
, Issue.5
, pp. 1088-1094
-
-
Sandborn, W.J.1
Hanauer, S.B.2
Katz, S.3
Safdi, M.4
Wolf, D.G.5
Baerg, R.D.6
Tremaine, W.J.7
Johnson, T.8
Diehl, N.N.9
Zinsmeister, A.R.10
|